Teva Pharma (TEVA) and Active Biotech Complete Patient Enrollment for Second Pivotal Phase III Trial of Laquinimod
More News related to TEVA
- Trading Outlook for Novavax Inc. Issued by InvestorSoup.com
- Teva Pharmaceutical (TEVA) Announces Commercial Launch of Generic Allegra-D
- Teva Introduces Fexofenadine HCl and Pseudoephedrine HCl Extended-Release Tablets; An Alternative to Allegra-D(R) 12 Hour Tablets
- Teva Pharma (TEVA) Guides FY09, FY10 Inline With the Street
- Teva Pharma (TEVA) Posts Q3 EPS of $0.89, Beats by 1c
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech today announced completion of patient enrollment for the second pivotal Phase III clinical trial, BRAVO, evaluating the novel, oral once-daily immunomodulating compound, laquinimod, for the treatment of relapsing-remitting multiple sclerosis. BRAVO is a global clinical trial designed to evaluate the efficacy, safety and tolerability of laquinimod versus placebo, and to provide risk-benefit data for laquinimod versus a currently available injectable treatment, Avonex(R).
The BRAVO study completed patient enrollment in June, recruiting more than 1,200 patients at 156 sites in the United States, Europe, Israel and South Africa.
Related Categories
Corporate NewsStocks Mentioned
+0.41Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
